智通财经获悉，周四，Allurion(ALUR.US)股价收涨超21%；截至发稿，股价在盘后交易中进一步飙升80%，此前有消息称该公司计划将其胃球囊减肥产品与GLP-1药物联合进行临床研究。Allurion在市场收盘前十分钟宣布，它正在计划一项研究， ...

马萨诸塞州纳蒂克 - 专注于肥胖治疗解决方案的Allurion Technologies, Inc. (NYSE: ALUR)通过新获得的美国专利扩大了其知识产权组合。根据 InvestingPro 的数据，该公司保持着73%的高毛利率，尽管在现金管理方面面临挑战。投资者可以通过InvestingPro的详细研究报告获得对Allurion财务健康和增长潜力的深入洞察。美国专利商标局授予了专利号12 ...

马萨诸塞州纳蒂克 - 以努力对抗肥胖和保持73%的高毛利率而闻名的Allurion Technologies, Inc. (NYSE: ALUR)今天披露了其计划进行一项临床研究，旨在提高肥胖治疗的效果。根据 InvestingPro ...

Allurion Technologies (ALUR) stock climbed 200% despite a ~7.4M stock and warrants offering announced by the company. Read ...

周四，Allurion（ALUR.US）股价收涨超21%；截至发稿，股价在盘后交易中进一步飙升80%，此前有消息称该公司计划将其胃球囊减肥产品与GLP-1药物联合进行临床研究。Allurion在市场收盘前十分钟宣布，它正在计划一项研究，将评估Allu ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to ...

Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% following the company's announcement of its plans to ...

Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves patients' muscle mass.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...